Subscribe
shutterstock_544602286_jon_bilous
Jon Bilous / Shutterstock.com
5 May 2022Big PharmaAlex Baldwin

Harvard, 10x say Vizgen infringes genomics patents

Harvard College and 10x Genomics have sued Vizgen, claiming that the Massachusetts-based biotech rival infringes five patents covering molecular analysis methods.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Vizgen accuses Harvard and 10x of patent licence cover-up
4 May 2023   Firm says patents-in-suit were developed using $19 million of public money | Biotech also cites “new evidence” in suit with Harvard and 10x.
Biotechnology
10x escalates genomics patents dispute at the UPC
8 June 2023   Biotech hoping for ‘pan-European injunctive relief’ | Vizgen CEO says lawsuits an ‘attempt to undermine innovation’.
Big Pharma
Harvard and 10x to face anti-competitive claims over genomics patents
13 July 2023   Delaware court permits counterclaims from Vizgen and Nanostring in separate suits | Firms say patents-in-suit were covered by ‘open and non-exclusive licenses’.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Vizgen accuses Harvard and 10x of patent licence cover-up
4 May 2023   Firm says patents-in-suit were developed using $19 million of public money | Biotech also cites “new evidence” in suit with Harvard and 10x.
Biotechnology
10x escalates genomics patents dispute at the UPC
8 June 2023   Biotech hoping for ‘pan-European injunctive relief’ | Vizgen CEO says lawsuits an ‘attempt to undermine innovation’.
Big Pharma
Harvard and 10x to face anti-competitive claims over genomics patents
13 July 2023   Delaware court permits counterclaims from Vizgen and Nanostring in separate suits | Firms say patents-in-suit were covered by ‘open and non-exclusive licenses’.

More on this story

Americas
Vizgen accuses Harvard and 10x of patent licence cover-up
4 May 2023   Firm says patents-in-suit were developed using $19 million of public money | Biotech also cites “new evidence” in suit with Harvard and 10x.
Biotechnology
10x escalates genomics patents dispute at the UPC
8 June 2023   Biotech hoping for ‘pan-European injunctive relief’ | Vizgen CEO says lawsuits an ‘attempt to undermine innovation’.
Big Pharma
Harvard and 10x to face anti-competitive claims over genomics patents
13 July 2023   Delaware court permits counterclaims from Vizgen and Nanostring in separate suits | Firms say patents-in-suit were covered by ‘open and non-exclusive licenses’.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?